Holen Sie sich die Stockscreener-App
262.82
1.11%
2.89
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$259.93
Offen:
$259.74
24-Stunden-Volumen:
5.54M
Relative Volume:
1.14
Marktkapitalisierung:
$464.43B
Einnahmen:
$62.82B
Nettoeinkommen (Verlust:
$3.60B
KGV:
129.63
EPS:
2.0274
Netto-Cashflow:
$19.98B
1W Leistung:
-0.58%
1M Leistung:
+0.42%
6M Leistung:
+25.85%
1J Leistung:
+11.10%
1-Tages-Spanne:
$257.87
$264.06
1-Wochen-Bereich:
$257.87
$268.93
52-Wochen-Spanne:
$190.75
$269.39
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
262.82 | 459.33B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,142.85 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.03 | 623.34B | 97.93B | 21.04B | 17.80B | 8.6278 |
MRK
Merck Co Inc
|
144.30 | 354.80B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.00 | 268.10B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2026-08-05 | Hochstufung | Erste Group | Hold → Buy |
| 2026-04-30 | Hochstufung | BofA Securities | Neutral → Buy |
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-04 | Herabstufung | DZ Bank | Buy → Hold |
| 2025-10-14 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie's Rinvoq Shows Promise in Vitiligo Trials, ABBV Stock Hig - GuruFocus
AbbVie long-term data buoys Rinvoq for vitiligo - Seeking Alpha
AbbVie Presents Long-Term RINVOQ® Data Showing Continued Repigmentation in Non-Segmental Vitiligo - Investing News Network
Why Is AbbVie (NYSE:ABBV) Suddenly a Must-Watch Healthcare Stocks Stock Today? - kalkinemedia.com
AbbVie to Host Third-Quarter 2026 Earnings Conference Call - Investing News Network
AbbVie to release Q3 2026 earnings on Oct 30 be... - Pluang
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - uk.finance.yahoo.com
ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? - Zacks Investment Research
AbbVie stock pre-market at EUR 231.40: minus 0.09 percent - AD HOC NEWS
New report explores the future of aesthetic treatments - kutv.com
AbbVie Stock: Buy, Sell, or Hold in October? - theglobeandmail.com
AbbVie’s eczema drug shows benefit in Phase 2; BioMarin lays off 117 - Endpoints News
AbbVie Reveals Positive Data for Eczema and Weight Loss Candidates - Benzinga
AbbVie unveils promising results for its obesity drug candidate - marketscreener.com
BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength - AOL.com
AbbVie (ABBV) Reports Promising Phase 1 Weight Loss Data for ABB - GuruFocus
AbbVie's ABBV-295 delivers up to 9.8% weight loss in Phase 1 (ABBV:NYSE) - Seeking Alpha
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 - Investing News Network
AbbVie's Zumilokibart Phase 2 Success Highlights Dividend Sustai - GuruFocus
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress - Investing News Network
At 16 weeks, all three doses of AbbVie’s eczema treatment improved skin more than placebo. - Stock Titan
AbbVie reports positive phase 2 data for Zumilokibart in atopic dermatitis - Seeking Alpha
Three late-breaking reports will be part of AbbVie's 60 research presentations on skin diseases. - Stock Titan
AbbVie Inc (ABBV) Stock Down 1.1% but Still Overvalued -- GF Sco - GuruFocus
Enterprise value of AbbVie, Inc. – HAN:4AB - TradingView
If You Invested $1000 In AbbVie Stock 10 Years Ago, You Would Have This Much Today - Benzinga
AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo! Finance Canada
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
Valkai Partners with Abbvie to Apply Advanced Ai Across Targeted Areas of Clinical Development - marketscreener.com
Defensive Dividends: 3 Companies Investors Can Rely On - TradingView
AbbVie (NYSE:ABBV) Wins Juvmo Approval for Parkinson's Disease - kalkinemedia.com
AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval - TradingView
AbbVie Shows Pipeline-Driven Upside Beyond Core Immunology Franchise, BofA Says - Yahoo Finance
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo - Yahoo Finance
AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development - Investing News Network
UnitedHealth, AbbVie And A Health Care Stock On CNBC’s ‘Final Trades’ - Benzinga
Ginkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium - marketscreener.com
AbbVie partners with Valkai to boost AI in clin... - Pluang
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium - Yahoo Finance
Is AbbVie (ABBV) A Bargain After FDA Approval Of JUVMO For Parkinson's? - Yahoo Finance
FDA Approves AbbVie's Juvmo for Parkinson Disease - Drug Topics
Can AbbVie’s Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation? - Yahoo Finance
AbbVie gets FDA approval for Parkinson’s disease drug Juvmo - Investing.com
AbbVie's Tavapadon Wins FDA Nod as First D1/D5 Agonist for Parkinson's - finance.biggo.com
AbbVie’s New Parkinson’s Pill Could Become a Billion-Dollar Drug, Analyst Says - Benzinga
AbbVie Wins FDA Approval for Parkinson’s Drug JUVMO - grafa.com
AbbVie Won FDA Approval for Parkinson’s Pill Juvmo. Here’s Why Management Already Expects a Slow Start - TIKR.com
AbbVie Receives FDA Approval for Parkinson’s Disease Drug Juvmo - Yahoo Finance
AbbVie (ABBV) Gains FDA Approval for Juvmo, Bolstering Parkinson's Portfolio - GuruFocus
U.S. FDA Approves AbbVie's JUVMO for Parkinson's Disease - Investing News Network
AbbVie Inc. (1ABBV.MI) stock price, news, quote and history - Yahoo Finance Singapore
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.34%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):